ADMA Biologics sees FY2026 total revenue of $530 mln to $560 mln
Company expects FY2026 adjusted net income of $170 mln to $200 mln
ADMA Biologics expects FY2026 adjusted EBITDA of $265 mln to $300 mln
Overview
U.S. biopharmaceutical firm's Q2 2026 revenue rose 2% yr/yr, driven by ASCENIV growth
Adjusted net income for Q2 2026 grew 8% yr/yr; adjusted EBITDA up 22%
Company repurchased 7.1 mln shares in Q2 as part of ongoing buyback program
Result Drivers
ASCENIV demand - Co said ASCENIV growth was driven by accelerating demand, increased physician adoption, broader prescriber engagement, new patient starts and higher patient utilization
BIVIGAM stabilization - Co said BIVIGAM demand stabilized during the quarter, resulting in sequential improvement in utilization and revenue
Product mix and manufacturing - Co attributed gross margin expansion to a favorable product mix shift toward ASCENIV and continued impact of yield-enhanced manufacturing process
ADMA•
